Business in the Burbs

Eastview-based Regeneron in deal with Tokyo company

March

Regeneron Pharmaceuticals Inc. of Eastview announced this morning that it has agreed to let a Japanese company use Regeneron technology in its research in return for an upfront payment of $20 million and the possibility of more payments in the future.

Astellas Pharma Inc. of Tokyo will use the VelocImmune technology in its quest to develop human antibody products. Astellas will make up to five future annual payments of $20 million based on the success of the research. If Astellas commercializes any products, it would pay Regeneron a royalty on sales.

Regeneron shares closed yesterday at $21.25, down 29 cents.

This entry was posted on Friday, March 30th, 2007 at 9:41 am by Allan Drury. You can follow any responses to this entry through the RSS 2.0 feed.
Category: Under contract

Print | Email

It is a condition of your use of the comment features associated with the blogs that you do not: Use the site to post or transmit any unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane or indecent information of any kind, including without limitation any transmissions constituting or encouraging conduct that would constitute a criminal offense, give rise to civil liability or otherwise violate any local, state, national or international law. You alone are responsible for the material you post or send. Refer to the Terms of Service.